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total testosterone concentrations.2 Guidelines on 
the evaluation of male hypogonadism also sug-
gest measurement of free testosterone levels in 
men with total testosterone levels that are near 
the lower limit of the normal range or those 
with conditions such as obesity that might affect 
levels of sex hormone–binding globulin.3 There-
fore, we wonder why the free testosterone level 
was not considered as an inclusion criterion and 
whether the findings of the trials differed accord-
ing to baseline concentrations of free testosterone 
or sex hormone–binding globulin.
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The authors reply: Perls and Stavropoulos et al. 
comment that the Testosterone Trials were not de-
signed to determine the risk of testosterone treat-
ment. Our trials were designed to implement the 
recommendation of the Institute of Medicine that 
trials of efficacy were needed before it could be 
determined whether a trial of risk was justified.1
Perls also notes that many participants in our 
trials were obese. Because obesity is common in 
the United States, the results should be general-
izable to men 65 years of age or older who have 
a low testosterone level. In spite of obesity, the 
free testosterone level in participants was also 
low, and testosterone treatment resulted in both 
symptomatic and objective benefits.
Stavropoulos et al. also ask about the effect 
of phosphodiesterase type 5 inhibitors on the 
sexual-function results. Fewer than 10% of men 
in the trials received phosphodiesterase type 5 
inhibitors, and this rate was well-balanced be-
tween the two study groups, so we are not able 
to compare outcomes between the two groups.
Mata et al. suggest that targeting relief of 
symptoms would have been better than targeting 
a serum testosterone concentration. The goal of 
the Testosterone Trials was to determine wheth-
er increasing the serum testosterone concentra-
tion to within the normal range for young men 
would reduce both symptoms and objective defi-
ciencies. We did not want to increase the serum 
testosterone level above normal because of the 
concern that doing so would increase risk.
Laurent et al. propose that the level of low free 
testosterone, rather than the level of total testos-
terone, should have been the basis for inclusion 
in the Testosterone Trials. As shown in Figure S2 
in the Supplementary Appendix of our article 
(available with the full text of the article at NEJM 
.org), median serum free testosterone levels were 
less than half of the median of the normal level 
at baseline and they more than doubled during 
treatment; this is similar to the pattern for total 
testosterone.
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Aspirin before Coronary Artery Surgery
To the Editor: The title of the article by Myles et 
al. (Feb. 25 issue)1 (“Stopping vs. Continuing As-
pirin before Coronary Artery Surgery”) indicates 
uncertainty about discontinuing aspirin before 
coronary-artery bypass grafting (CABG). How-
ever, the trial, Aspirin and Tranexamic Acid for 
Coronary Artery Surgery (ATACAS), does not ad-
dress that uncertainty. All patients discontinued 
aspirin at least 4 days before surgery, and risks of 
perioperative complications among patients who 
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started aspirin immediately before surgery were 
compared with risks among patients who started 
aspirin after surgery. Furthermore, the factorial 
design in which some patients were assigned to 
receive tranexamic acid precluded assessment of 
aspirin-related bleeding in half the patients who 
received aspirin.
Our additional concerns about this trial include 
the use of enteric-coated aspirin, which has delayed 
and unpredictable absorption,2 and the 100-mg 
dose of aspirin, which is lower than the recom-
mended loading dose for patients with an acute 
condition.3 Also, the definition of myocardial in-
farction changed from the definition that is cur-
rently accepted4 to one that requires elevations in 
enzyme levels that are less marked than those 
recommended for patients after CABG5 (the com-
posite outcome was twice the rate predicted on 
the basis of earlier studies, and almost 75% of the 
patients who reached the composite outcome had 
myocardial infarction).
The randomized, double-blind design and large 
planned sample size were major advances over 
earlier, less rigorous designs.6 Unfortunately, with 
the serious design flaws in this trial, the negative 
result does not resolve clinical uncertainty about 
whether patients should discontinue aspirin be-
fore CABG.
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To the Editor: The ATACAS trial by Myles et al. 
shows neither benefits nor disadvantages of a 
single dose of aspirin 1 to 2 hours before elective 
CABG in patients after aspirin has been discontin-
ued for at least 4 days. Rates of thrombotic and 
bleeding complications were similar among pa-
tients who received aspirin and those who did not.
Unfortunately, the study design does not an-
swer the question of whether it is best to stop or 
continue aspirin in patients undergoing CABG, 
since the influence of the “rebound phenomenon” 
after discontinuation of aspirin is not quantified.1 
The occurrence of the rebound phenomenon is 
hinted at by the unusually high rate of postop-
erative myocardial infarction (14.8%).
Furthermore, with the current emphasis on 
postoperative events, the preoperative risks of dis-
continuing antiplatelet drugs remain to be eluci-
dated. Discontinuation of antiplatelet therapy is 
not without risks,1 especially among patients with 
a recent acute coronary syndrome.2 We were sur-
prised that 7.5% of the patients in the trial had 
had a recent myocardial infarction, and most had 
stopped taking an antiplatelet drug at least 4 days 
before CABG.
The dilemma regarding continuation or dis-
continuation of aspirin before CABG remains to 
be solved. A trial in which patients are randomly 
assigned to either continue or discontinue aspirin 
5 to 7 days before surgery, with assessment of both 
preoperative and postoperative events, may be 
more appropriate than the method used in the 
trial by Myles et al.
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The authors reply: The concern about our title 
expressed by Alkhodair and Cairns overlooks the 
practical aims of the trial in that the reason pa-
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tients were asked to discontinue aspirin before 
surgery was because of the perceived bleeding risk 
during and after surgery. That is, bleeding risk was 
not associated with aspirin until the actual surgery. 
We found that treatment with aspirin at a single 
dose of 100 mg before surgery did not pose any 
significant bleeding risk. Hence, there is no reason 
for patients to discontinue aspirin before coronary 
artery surgery because of this concern. Tranexamic 
acid is an antifibrinolytic drug that may or may 
not reduce aspirin-related bleeding; an evaluation 
with our factorial design is under way.
Enteric-coated aspirin may have less reliable 
absorption than an immediate-release formula-
tion. However, enteric-coated aspirin is commonly 
used and has clearly been shown to be effective in 
patients with acute coronary syndromes.1 Patients 
with ST-elevation myocardial infarction are differ-
ent from those undergoing coronary artery sur-
gery; the latter have a much higher bleeding risk 
and there is less urgency to induce platelet inhi-
bition. The same guideline highlighted by Alkho-
dair and Cairns2 recommends a preferred main-
tenance dose of aspirin as low as 81 mg daily, and 
it is with this dose that most patients present for 
surgery.
The universal definition of postoperative myo-
cardial infarction was used in our trial, and the 
same expert group that created that definition in-
cluded isolated markedly elevated troponin levels 
as being sufficient to diagnose myocardial infarc-
tion.3 If we remove the latter events from our re-
sults, we lose 17 myocardial infarction events in 
the aspirin group and 15 myocardial infarction 
events in the placebo group; this reduces the myo-
cardial infarction event rate by only 1.5 percent-
age points, and the point estimate of an aspirin 
effect remains unchanged (risk ratio, 0.94). An 
isolated but marked elevation in the troponin 
level after CABG is prognostically important.3,4
We accept the observation by Li et al. that our 
study design cannot quantify the influence of the 
aspirin rebound phenomenon, but this does not 
explain the high rate of postoperative myocardial 
infarctions reported in our trial. Troponin surveil-
lance has greater sensitivity than creatine kinase–
myocardial band in detecting small myocardial 
infarctions.3
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Incidence of Dementia over Three Decades  
in the Framingham Heart Study
To the Editor: Satizabal et al. (Feb. 11 issue)1 
report a steady decline in the incidence of demen-
tia during the past three decades, represented by 
5-year epochs, among participants in the Fram-
ingham Heart Study. We suspect that a statistical 
bias, truncation by death, might to some extent 
contribute to this finding. Each epoch included 
participants who were 60 years of age or older and 
dementia-free at the start of the study; participants 
who were still dementia-free at the end of an epoch 
could be included in the following epoch. In their 
analysis, in each epoch, data for participants were 
censored at the last date they were known to be 
dementia-free or at the date of death. Because of 
discrete follow-up visits, death could have preclud-
ed the observation of the onset of dementia, a fac-
tor that is known to result in an underestimated 
incidence of dementia2 and bias in Cox model es-
timates.3,4 This factor was also pointed out in the 
recent guidelines of the Methods in Longitudinal 
Research on Dementia (MELODEM) Initiative.5 
Over time, truncation by death bias gets even larg-
er, which cannot be accounted for in age-adjusted 
estimates. To judge this problem, it would be in-
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